A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission

Trial Profile

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Dec 2015 Results will be published at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, according to a Kura Oncology media release.
    • 03 Dec 2015 Results published in the Kura Oncology Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top